Bharat Parenterals acquires additional stake in Innoxel

25 Jun 2024 Evaluate

Bharat Parenterals (BPL) has strategically acquired an additional 99,85,477 equity shares of Innoxel Lifesciences (Innoxel) at Rs 64.90 per share on preferential basis, by valuing the Innoxel for around Rs 648 crore. This led to increase in its stake of BPL from 51% to 55.89% in Innoxel.

Innoxel is an emerging CDMO specialising in aseptic production of Injectable vials, Pre-filled syringes and oral liquids. The first set of products from Innoxel has already commenced for exhibit batches and eventually will file with regulatory authorities. Innoxel has been designed, built, and now operated to enable it to be compliant with USFDA, EUGMP and MHRA norms. 

Further, the board of BPL has proposed to acquire 2,50,000 equity shares (100% equity) of Varenyam Healthcare (VHPL) from current shareholders, enhancing its control and operational efficiency.

BPL has also proposed, subject to necessary approvals, acquisition of an additional 18,00,000 equity shares of Varenyam Biolifesciences (VBPL), valuing VBPL at around Rs 2.40 crore, raising BPL stake to 100%. The consideration for this acquisition involves a share swap, with BPL issuing 16,261 equity shares to VBPL shareholders as per the swap ratio identified by the Registered Valuer.

Bharat Parenterals is engaged in to the business of the Pharmaceuticals & Drugs.

Bharat Parenterals Share Price

1201.55 -3.70 (-0.31%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×